Efficacy and Safety of Kushenin combined with Adefovir Dipivoxil in the Treatment of Chronic Hepatitis B: A Systematic Review_Chinese Journal of Evidence-Based Medicine

Authors：

SU Na ^1,2 , WU Bin ² , XU Ting ² ,  TANG Yao ²

1. West China Medical School, Sichuan University, Chengdu 610041, China;2. Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China;

Corresponding author：

TANG Yao, Email: zoya159@163.com

Keywords：

Kushenin; Adefovir Dipivoxil; Chronic Hepatitis B; Systematic review; Meta-analysis; Randomized controlled trial

DOI：

10.7507/1672-2531.20100567

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To review the efficacy and safety of Kushenin combined with Adefovir Dipivoxil for Chronic Hepatitis B (CHB).
Method 　Randomized controlled trails of Kushenin combined with Adefovir Dipivoxil for CHB were gathered from PubMed, CBMdisc (1978 to 2009), and CSJD (1989 to 2009), while other relative researches were searched manually; every research was evaluated, and then analyzed with RevMan 5.0.0 software.
Result 　Ten randomized controlled trials were included; among total 855 patients, 436 were in trial group and the other 419 were in control group. As the Meta-analysis showed, the therapeutic effect of kushenin combined with Adefovir Dipivoxil was better than that of Adefovir Dipivoxil in aspects of improving the negative rate of serum ALT (RR=1.28, 95%CI 1.17 to 1.40), the negative rate of serum HBV-DNA (RR=1.27, 95%CI 1.13 to 1.42), the negative rate of serum HBeAg (RR=1.80, 95%CI 1.32 to 2.44), and the conversion rate of HBeAg and anti-HBe (RR2.06, 95%CI 1.43 to 2.95).
Conclusion 　Kushenin combined with Adefovir Dipivoxil in treating CHB can improve the conversion rate of HBeAg and anti-HBe and further take better therapeutic effect.

Citation： SU Na,WU Bin,XU Ting,TANG Yao. Efficacy and Safety of Kushenin combined with Adefovir Dipivoxil in the Treatment of Chronic Hepatitis B: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2010, 10(10): 1182-1187. doi: 10.7507/1672-2531.20100567 Copy

1.	Liaw Y F, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol, 2003, 18(3): 239-245.
2.	Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to Lamivudine. Hepatolopy, 1998, 27(6): 6701.
3.	杨诗杰. 苦参素联合拉米夫定对慢性乙型肝炎血清HBsAg影响的Meta 分析. 实用医学杂志, 2008, 24(13): 2220-2223.
4.	中华医学会传染病与寄生虫病学分会和肝脏分会. 病毒性肝炎防治方案 . 中华肝脏病杂志, 2000, 8(6): 324-329.
5.	Juni P, Altman DG, Eger M. Assessing the quality of controlled clinical trails. BMJ, 2001, 323: 42-46.
6.	Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008.
7.	Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002, 21(11): 1539-1558.
8.	江堤, 扬光, 罗万蓉. 阿德福韦联合苦参素治疗HBeAg 阴性慢性乙肝效果研究. 现代预防医学, 2009, 36(8): 1587-1590.
9.	姬宪立, 姬瑞英, 张佰健. 阿德福韦脂联合苦参素治疗慢性乙型肝炎的疗效观察. 中国实用医药, 2006, 1(1): 2-3.
10.	颜晶晓. 阿德福韦酯合苦参素胶囊治疗慢性乙型肝炎. 浙江中西医结合杂志, 2008, 18(3): 172-173.
11.	陆宁, 徐园. 阿德福韦酯联合苦参素治疗YMDD 变异慢性乙型肝炎患者的疗效. 中国医院药学杂志, 2008, 28(17): 1484-1486.
12.	吕开雪. 阿德福韦酯联合苦参素治疗拉米夫定耐药慢性乙肝的研究. 现代医药卫生, 2007, 23(20): 3011-3012.
13.	韦健盛, 张玲. 阿德福韦酯联合苦参素治疗慢性乙型肝炎33例. 实用中医内科杂志, 2008, 22(3): 38-40.
14.	李春玉, 张学武. 阿德福韦酯联合苦参素治疗慢性乙型肝炎的临床研究. 实用肝脏病杂志, 2008, 11(6): 370-372.
15.	赵端壁. 阿德福韦酯与苦参素联合治疗HBeAg 阳性慢性乙型肝炎的疗效观察. 实用医学杂志, 2008, 24(1): 117-118.
16.	刘兴峰. 苦参素胶囊联合阿德福韦酯治疗慢性乙型肝炎的临床研究. 河北医学, 2006, 13(3): 256-258.
17.	陈岩. 苦参素联合阿德福韦酯治疗慢性乙型肝炎122例. 黑龙江医药, 2008, 21(1): 74-76.

1. Liaw Y F, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol, 2003, 18(3): 239-245.
2. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to Lamivudine. Hepatolopy, 1998, 27(6): 6701.
3. 杨诗杰. 苦参素联合拉米夫定对慢性乙型肝炎血清HBsAg影响的Meta 分析. 实用医学杂志, 2008, 24(13): 2220-2223.
4. 中华医学会传染病与寄生虫病学分会和肝脏分会. 病毒性肝炎防治方案 . 中华肝脏病杂志, 2000, 8(6): 324-329.
5. Juni P, Altman DG, Eger M. Assessing the quality of controlled clinical trails. BMJ, 2001, 323: 42-46.
6. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008.
7. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002, 21(11): 1539-1558.
8. 江堤, 扬光, 罗万蓉. 阿德福韦联合苦参素治疗HBeAg 阴性慢性乙肝效果研究. 现代预防医学, 2009, 36(8): 1587-1590.
9. 姬宪立, 姬瑞英, 张佰健. 阿德福韦脂联合苦参素治疗慢性乙型肝炎的疗效观察. 中国实用医药, 2006, 1(1): 2-3.
10. 颜晶晓. 阿德福韦酯合苦参素胶囊治疗慢性乙型肝炎. 浙江中西医结合杂志, 2008, 18(3): 172-173.
11. 陆宁, 徐园. 阿德福韦酯联合苦参素治疗YMDD 变异慢性乙型肝炎患者的疗效. 中国医院药学杂志, 2008, 28(17): 1484-1486.
12. 吕开雪. 阿德福韦酯联合苦参素治疗拉米夫定耐药慢性乙肝的研究. 现代医药卫生, 2007, 23(20): 3011-3012.
13. 韦健盛, 张玲. 阿德福韦酯联合苦参素治疗慢性乙型肝炎33例. 实用中医内科杂志, 2008, 22(3): 38-40.
14. 李春玉, 张学武. 阿德福韦酯联合苦参素治疗慢性乙型肝炎的临床研究. 实用肝脏病杂志, 2008, 11(6): 370-372.
15. 赵端壁. 阿德福韦酯与苦参素联合治疗HBeAg 阳性慢性乙型肝炎的疗效观察. 实用医学杂志, 2008, 24(1): 117-118.
16. 刘兴峰. 苦参素胶囊联合阿德福韦酯治疗慢性乙型肝炎的临床研究. 河北医学, 2006, 13(3): 256-258.
17. 陈岩. 苦参素联合阿德福韦酯治疗慢性乙型肝炎122例. 黑龙江医药, 2008, 21(1): 74-76.

Previous Article
Asarone Injection in Treating Respiratory Disease: A Meta-analysis
Next Article
Bisphosphonates for Multiple Myeloma: A Systematic Review

Chinese Journal of Evidence-Based Medicine

Efficacy and Safety of Kushenin combined with Adefovir Dipivoxil in the Treatment of Chronic Hepatitis B: A Systematic Review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content